Anglia Ruskin University

File(s) under embargo





until file(s) become available

COVID-19 Susceptibility and Clinical Outcomes in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis

journal contribution
posted on 2023-09-01, 15:06 authored by Min Ho Lee, Han Jacob Li, Paul Wasuwanich, Sung Eun Kim, Jong Yeob Kim, Gwang Hun Jeong, Seoyeon Park, Jae Won Yang, Min Seo Kim, Dong Keon Yon, Seung Won Lee, Ai Koyanagi, Louis Jacob, Eun-Young Kim, Jae Hee Cheon, Jae Il Shin, Lee Smith
The susceptibility, risk factors, and prognosis of COVID-19 in patients with inflammatory bowel disease (IBD) remain unknown. Thus, our study aims to assess the prevalence and clinical outcomes of COVID-19 in IBD. We searched PubMed, EMBASE, and medRxiv from 2019 to 1 June 2022 for cohort and case-control studies comparing the prevalence and clinical outcomes of COVID-19 in patients with IBD and in the general population. We also compared the outcomes of patients receiving and not receiving 5-aminosalicylates (ASA), tumour necrosis factor antagonists, biologics, systemic corticosteroids, or immunomodulators for IBD. Thirty five studies were eligible for our analysis. Pooled odds ratio of COVID-19-related hospitalisation, intensive care unit (ICU) admission, or death in IBD compared to in non-IBD were 0.58 (95% confidence interval (CI) = 0.28–1.18), 1.09 (95% CI = 0.27–4.47), and 0.67 (95% CI = 0.32–1.42), respectively. Inflammatory bowel disease was not associated with increased hospitalisation, ICU admission, or death. Susceptibility to COVID-19 did not increase with any drugs for IBD. Hospitalisation, ICU admission, and death were more likely with 5-ASA and corticosteroid use. COVID-19-related hospitalisation (Odds Ratio (OR): 0.53; 95% CI = 0.38–0.74) and death (OR: 0.13; 95% CI = 0.13–0.70) were less likely with Crohn's disease than ulcerative colitis (UC). In conclusion, IBD does not increase the mortality and morbidity of COVID-19. However, physicians should be aware that additional monitoring is needed in UC patients or in patients taking 5-ASA or systemic corticosteroids.



  • Yes

Publication title

Reviews in Medical Virology





File version

  • Accepted version


  • eng

Legacy posted date


Legacy creation date


Legacy Faculty/School/Department

COVID-19 Research Collection

Usage metrics

    ARU Outputs


    No categories selected